BIOMARIN PHARMACEUTICAL INC

Key metrics

Financial performance

Over the last 9 fiscal years BIOMARIN PHARMACEUTICAL INC's revenue grew from $1.12B to $3.22B, a compound annual growth rate of 12.5%. Net profit margin expanded from -56.4% to 10.8% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (2,709 filings)

Recent press releases

• BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia2026-05-20

  _Study met primary endpoint, exceeding expectations with a highly statistically significant improvement in annualized growth velocity (AGV, change from baseline) of 2.33 cm/yr compared to placebo at week 52, as well as statistically significant increases in standing height and height Z-score_

• Detailed results from the ENERGY 3 study will be presented at an upcoming medical meeting.2026-05-18

  BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency

• BioMarin Reports First Quarter 2026 Financial and Operating Results2026-05-04

  First Quarter 2026 Total Revenues Increased Year-over-year to $766 million

• Corporate Responsibility Report opens in new window2026-05-02

  BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting

• BioMarin Completes Acquisition of Amicus Therapeutics2026-04-27

  _Acquisition Adds Galafold_ _®_ _(migalastat) for Fabry Disease and Pombiliti_ _®_ _(cipaglucosidase alfa-atga) + Opfolda_ _®_ _(miglustat) for Pompe Disease to BioMarin's Commercial Portfolio_

Similar companies

The largest companies sharing BIOMARIN PHARMACEUTICAL INC's SEC industry classification (pharmaceutical preparations).